The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis
Open accessAbstract
CONTEXT: Use of generic drugs, which are bioequivalent to brand-name drugs, can help contain prescription drug spending. However, there is concern among patients and physicians that brand-name drugs may be clinically superior to generic drugs. OBJECTIVES: To summarize clinical evidence comparing generic and brand-name drugs used in cardiovascular disease and to assess the perspectives of editorialists on this issue. DATA SOURCES: Systematic searches of peer-reviewed publications in MEDLINE, EMBASE, and International Pharmaceutical Abstracts from January 1984 to August 2008. STUDY SELECTION: Studies compared generic and brand-name cardiovascular drugs using clinical efficacy and safety end points. We separately identified editorials addressing generic substitution. DATA EXTRACTION: We extracted variables related to the study design, setting, participants, clinical end points, and funding. Methodological quality of the trials was assessed by Jadad and Newcastle-Ottawa scores, and a meta-analysis was performed to determine an aggregate effect size. For editorials, we categorized authors' positions on generic substitution as negative, positive, or neutral. RESULTS: We identified 47 articles covering 9 subclasses of cardiovascular medications, of which 38 (81%) were randomized controlled trials (RCTs). Clinical equivalence was noted in 7 of 7 RCTs (100%) of beta-blockers, 10 of 11 RCTs (91%) of diuretics, 5 of 7 RCTs (71%) of calcium channel blockers, 3 of 3 RCTs (100%) of antiplatelet agents, 2 of 2 RCTs (100%) of statins, 1 of 1 RCT (100%) of angiotensin-converting enzyme inhibitors, and 1 of 1 RCT (100%) of alpha-blockers. Among narrow therapeutic index drugs, clinical equivalence was reported in 1 of 1 RCT (100%) of class 1 antiarrhythmic agents and 5 of 5 RCTs (100%) of warfarin. Aggregate effect size (n = 837) was -0.03 (95% confidence interval, -0.15 to 0.08), indicating no evidence of superiority of brand-name to generic drugs. Among 43 editorials, 23 (53%) expressed a negative view of generic drug substitution. CONCLUSIONS: Whereas evidence does not support the notion that brand-name drugs used in cardiovascular disease are superior to generic drugs, a substantial number of editorials counsel against the interchangeability of generic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Meta-analysis of experiments with matched groups or repeated measures designs
Dunlap, W. P., Cortina, J. M., Vaslow, J. B., & Burke, M. J. (1996) · Psychological Methods · doi:10.1037/1082-989x.1.2.170 · Cited by 1,693 · cited 3×
“Martin et al,44 1984 Lasix vs furosemide 12 (18-42)/1 dose of each with washout Bioequivalency study: RCT with crossover Healthy subjects (non-US) 0 Statistically nonsignificant trend of lower urine output (P = .”
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 874
Interventions to Enhance Medication Adherence in Chronic Medical Conditions: A Systematic Review
Kripalani, S., Yao, X., & Haynes, R. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.6.540 · Cited by 810
Conflict of Interest in the Debate over Calcium-Channel Antagonists
Stelfox, H. T., Chua, G., O'Rourke, K., & Detsky, A. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380206 · Cited by 615
Comparing effect sizes of independent studies.
Rosenthal, R., & Rubin, D. B. (1982) · Psychological Bulletin · doi:10.1037//0033-2909.92.2.500 · Cited by 406
Shrank, W. H., Hoang, T., Ettner, S. L., Glassman, P. A., Nair, K., DeLapp, D., Dirstine, J., Avorn, J., & Asch, S. M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.332 · Cited by 343
Patients’ Perceptions Of Generic Medications
Shrank, W. H., Cox, E. R., Fischer, M. A., Mehta, J., & Choudhry, N. K. (2009) · Health Affairs · doi:10.1377/hlthaff.28.2.546 · Cited by 255
Bioequivalence and other unresolved issues in generic drug substitution
Meredith, P. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80340-5 · Cited by 213
Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less?
Fischer, M. A., & Avorn, J. (2004) · JAMA · doi:10.1001/jama.291.15.1850 · Cited by 183
Variable Furosemide Absorption and Poor Predictability of Response in Elderly Patients
Murray, M. D., Haag, K. M., Black, P., Hall, S. D., & Brater, D. C. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03681.x · Cited by 107
Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology
Riechelmann, R. P., Wang, L. E., O'Carroll, A., & Krzyzanowska, M. K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2482 · Cited by 73
Implications of intraindividual variability in bioavailability studies of furosemide
Grahn�n, A., Hammarlund, M., & Lundqvist, T. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00556898 · Cited by 73
Generic Drug Substitution Revisited
Strom, B. L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162306 · Cited by 71
Meredith, P. (1996) · Drug Safety · doi:10.2165/00002018-199615040-00001 · Cited by 68
Management of Narrow Therapeutic Index Drugs
Burns, M. M. (1999) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1008829403320 · Cited by 62
Park, J. Y., Kim, K., Lee, G.-S., Park, P.-W., Kim, S.-L., Lee, Y.-S., Lee, Y., & Shin, E.-K. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90071-9 · Cited by 54
Fischer, M. A., & Avorn, J. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.872 · Cited by 53
Generic substitution: issues for problematic drugs.
Henderson, J. D., & Esham, R. H. (2001) · PubMed · Cited by 47
Brand and generic medications: Are they interchangeable?
Al‐Jazairi, A. S., Balhareth, S. S., Eqtefan, I., & Al‐Suwayeh, S. A. (2008) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2008.33 · Cited by 39
Are Brand-Name and Generic Warfarin Interchangeable? Multiple N-of-1 Randomized, Crossover Trials
Pereira, J. A., Holbrook, A. M., Dolovich, L. R., et al. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g003 · Cited by 37
Relevance of pharmacokinetics in narrow therapeutic index drugs
Benet, L. Z. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(99)00083-4 · Cited by 28
Brand and generic medications : Are they interchangeable?
Al‐Jazairi, A. S., Bhareth, S., Eqtefan, I., & Al‐Suwayeh, S. A. (2008) · Annals of Saudi Medicine · doi:10.4103/0256-4947.51758 · Cited by 20
DeCara, J. M., Croze, S., & Falk, R. H. (1998) · CHEST Journal · doi:10.1378/chest.113.2.261 · Cited by 18
Effect of two formulations of a beta blocker on fibrinolytic response to maximum exercise
Elsayed, M., & Davies, B. (1989) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-198908000-00005 · Cited by 18
The debate over substitution policy: Its evolution and scientific basis
Schwartz, L. L. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90584-4 · Cited by 12
Comparison of the Effect of Two Metoprolol Formulations on Total Ischaemic Burden
Bongers, V., & Sabin, G. V. (1999) · Clinical Drug Investigation · doi:10.2165/00044011-199917020-00004 · Cited by 4
Cited by
Dumbreck, S., Flynn, A., Nairn, M., Wilson, M., Treweek, S., Mercer, S. W., Alderson, P., Thompson, A., Payne, K., & Guthrie, B. (2015) · BMJ · doi:10.1136/bmj.h949 · Cited by 339
Davit, B. M., Nwakama, P. E., Buehler, G. J., Conner, D. P., Haidar, S. H., Patel, D. T., Yang, Y., Yu, L. X., & Woodcock, J. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m141 · Cited by 330
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
WOUTERS, O. J., KANAVOS, P. G., & McKEE, M. (2017) · The Milbank Quarterly · doi:10.1111/1468-0009.12279 · Cited by 287
Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: A Cohort Study
Gagne, J. J., Choudhry, N. K., Kesselheim, A. S., Polinski, J. M., Hutchins, D., Matlin, O. S., Brennan, T. A., Avorn, J., & Shrank, W. H. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2942 · Cited by 155
“Generic drugs have been shown in small, short, randomized trials (14, 15) to be clinically equivalent to their brandname counterparts, as required for approval by the U.”
Self-citationMedicine shortages in Fiji: A qualitative exploration of stakeholders’ views
Walker, J., Chaar, B. B., Vera, N., Pillai, A. S., Lim, J. S., Bero, L., & Moles, R. J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178429 · Cited by 57
Metadata
- Authors
- Kesselheim, A. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-12-03
- Volume
- 300
- Issue
- 21
- Pages
- 2514
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1989247444
- Cited by
- 431
- References
- 33
- FWCI
- 59.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.